Sangamo Therapeutics, Inc.(NASDAQ : SGMO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.06%||734.70||2.6%||$779.09m|
|GILD||Gilead Sciences, Inc.||2.95%||64.16||1.0%||$546.30m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.48%||298.85||1.9%||$428.89m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.24%||4.15||0.7%||$290.10m|
|SAVA||Cassava Sciences, Inc.||1.98%||42.32||0.0%||$200.98m|
|BMRN||BioMarin Pharmaceutical, Inc.||1.04%||87.60||4.2%||$86.09m|
|PRTA||Prothena Corp. Plc||0.49%||62.13||13.8%||$84.42m|
|NRBO||NeuroBo Pharmaceuticals, Inc.||2.56%||13.60||0.0%||$82.32m|
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.